The acquisition gives the German company a promising blood disorder medicine that passed a Phase 2 test and could threaten a ...
Roche is paying Hansoh $400 million up front in a broad deal involving several ADCs. Elsewhere, another top investor formed a ...
Early CDMO engagement can be valuable, particularly when it helps development teams understand technical requirements, ...
Months after the FDA rejected its treatment for a rare light-sensitivity disease, the biotech claimed success in a Phase 3 ...
An early data check showed the shot didn’t delay tumor progression in a form of head and neck cancer, though BioNTech is ...
Yet one factor remains consistently underestimated: physical connectivity or fluid management. The tubing, connectors, ...
The offering will support a trio of medicines in or nearing clinical testing, as well as earlier research into RNAi ...
Fresh off a $150 million IPO, Tom Miller spoke to BioPharma Dive about the roadshow process and how he sees AI’s role in drug ...
One lawyer involved noted how it's yet another example of Paragon and key investor Fairmount — which have helped transform ...
In a first, a subcutaneously administered RNA interference medicine crossed into the brain and plummeted levels of a protein ...
The latest installment in BioPharma Dive’s data visualization-focused series includes a look at Moderna’s meteoric rise in 2026 and a sudden deal surge from Roche.
Only the lower of two tested doses of the idiopathic pulmonary fibrosis drug admilparant met the trial’s main objective, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results